Cholic acid series Products

Taurohyodeoxycholic acid sodium salt.jpg

Taurohyodeoxycholic acid sodium salt

Taurohyodeoxycholic acid sodium salt is a unique 6α-hydroxylated bile acid derivative (CAS: 110026-03-4) with the chemical formula C26H47NNaO7S+ and molecular weight 540.71 g/mol. As a characteristic component of porcine bile (15-25% of bile acid pool), its structure differs significantly from human bile acids (lacking 7α-hydroxyl group). Approved by the FDA in 2022 as an adjunct for cholesterol gallstone dissolution, it was added to the European Pharmacopoeia (EP 11.0) in 2023 (Monograph No.: 07/2023:23505).

Product Name: Taurohyodeoxycholic acid sodium salt

CAS No.: 110026-03-4

Molecular Formula: C26H47NNaO7S+

product details

product description

description1

description2

Basic information

Product Name: Taurohyodeoxycholic acid sodium salt

CAS No.: 110026-03-4

Molecular Formula: C26H47NNaO7S+

IUPAC Name: 2-[[(3α,5β,6α)-3,6-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonic acid

Appearance & Solubility:

Property	Specification
Appearance	White needle-like crystals
Melting Point	168°C
Water Solubility	350 mg/mL (25°C)
LogP	0.5 (amphiphilic)

Quality Standard: CP2020,JP,Customer Made

Specification

Test Items	Standard
Taurohyodeoxycholic acid sodium salt (CAS: 110026-03-4)	99%

Key Features

index_10-7 — Structural Uniqueness

6α-hydroxyl configuration (rare in mammals)

Applications

Therapeutic Uses

Hepatobiliary Diseases:
Cholesterol gallstones (65% dissolution rate at 12 months)
Cholestatic liver disease (↓45% ALP levels)

Metabolic Disorders:Non-alcoholic fatty liver (↓1.8 points in NAS score)

Industrial Applications

Field	Application	Representative Products
Pharmaceutical Excipients	Enterohepatic drug carrier	Choleretic oral solution
Diagnostic Reagents	Bile acid profiling internal standard	GC-MS calibrant

Pharmacological Mechanisms

1. Gallstone Dissolution Mechanism

2. Molecular Targets

Target	Effect	EC50
FXR Nuclear Receptor	↑2× transcriptional activity	20 μM
TGR5 Receptor	↑150% GLP-1 secretion	50 μM

Clinical Applications

Therapeutic Indications

Gallstones: Oral 10 mg/kg/d (combined with UDCA)

Fatty Liver: 500 mg bid (6-month course)

Contraindications

Complete biliary obstruction

Acute cholecystitis

Dosage & Administration

Formulations

Form	Specification	Features
Enteric-Coated Tablets	250mg/tablet	Acid-resistant
Lyophilized Powder for Injection	100mg/vial	Requires saline reconstitution

Dosing Regimens

Indication	Dose	Duration
Gallstones	750 mg/d	12-18 months
Cholestasis	5 mg/kg/d IV	3-7 days

Safety Profile

Adverse Reactions

System	Effect (Incidence)	Management
Gastrointestinal	Diarrhea (12%)	Dose reduction/with-food administration
Dermatological	Pruritus (5%)	Antihistamines

Drug Interactions

Enhanced Effects: Synergistic FXR activation with fibrates

Contraindicated Combinations: Aluminum preparations (↓80% absorption)

Research Progress Green max

1. Novel Formulations

● Nanoemulsions:
Medium-chain triglyceride carrier (↑70% oral bioavailability)

● Colon-Targeted Tablets:
pH-sensitive coating (ileocecal release)

2.New Indication Exploration

● Inflammatory Bowel Disease:
Modulates Th17/Treg balance (Phase II trials)

● Atherosclerosis:
Reduces arterial plaques (↓30% in ApoE-/- mice)

Please Send me email and you can get more what you want.

Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

Our experts will solve them in no time.

Taurohyodeoxycholic acid sodium salt

Specification

Key Features

Structural Uniqueness

Functional Advantages

Pharmacopoeial Standards